IBD patients on Aza/Mp aware of skin cancer risk
Research type
Research Study
Full title
Are patients with Inflammatory Bowel Disease on immunomodulators aware of the increased risk of skin cancer and do they carry out sun prevention measures?
IRAS ID
212081
Contact name
Simon Whiteoak
Contact email
Sponsor organisation
University of Southampton
Duration of Study in the UK
0 years, 2 months, 27 days
Research summary
This study looks at patients who have a diagnosis of inflammatory bowel disease (Crohn's disease and ulcerative colitis) who are on either azathioprine or mercaptopurine for treatment of their condition. These drugs increase the patients' skin photosensitivity to the sun meaning they are at increased risk of non-melanoma skin cancer. The study centre is situated in a higher incidence area of skin cancer. The study hopes to find out if patients are aware of this risk, do they carry out any sun prevention measures and do they check their skin for any signs of skin cancer.
In brief the study will require participants meeting the inclusion criteria to engage in a recorded telephone interview asking questions about any past history of skin cancer, their attitude towards sun safety and the measures they take.
REC name
East of England - Cambridge East Research Ethics Committee
REC reference
18/EE/0322
Date of REC Opinion
29 Oct 2018
REC opinion
Further Information Favourable Opinion